Abstract
The potential for gene therapy to cure a wide range of diseases has lead to high expectations and a great increase in research efforts in this area. At present, viral vectors are the most efficient means of delivering a corrective gene into human cells. While a number of different viral vectors are under development, retroviral vectors are currently the most common type used in clinical trials today. However, the production of retroviral vectors for gene therapy applications faces a number of challenges. Of primary concern is the low titre of vector stocks produced by packaging cells in culture and the inherent instability of retroviral vector activity. The problems facing large-scale retroviral vector production are outlined in this review and the research efforts by a number of groups who have attempted to optimise production methods are presented. (C) 2002 Elsevier Science Inc. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 1-31 |
| Number of pages | 31 |
| Journal | Biotechnology Advances |
| Volume | 20 |
| Publication status | Published - 1 Jan 2002 |
